U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07377279) titled 'Acupuncture and Compression for the Prevention of CIPN in Breast Cancer Patients' on Jan. 14.
Brief Summary: As a core component of comprehensive breast cancer treatment, chemotherapy frequently induces chemotherapy-induced peripheral neuropathy (CIPN), particularly with taxane-based agents. The incidence of CIPN reaches 68.1% within the first month of chemotherapy, and over 30% of patients experience persistent symptoms for more than 6 months. The resulting sensorimotor dysfunction significantly impairs patients' quality of life, necessitates dose reduction or treatment discontinuation, and ultimately affects survival outcomes. Cur...